Suraksha Diagnostic Ltd (SURAKSHA) — shareholding pattern, promoter holding, financials and share price
About Suraksha Diagnostic Ltd (SURAKSHA)
Suraksha Diagnostic Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as SURAKSHA and on the BSE under scrip code 544293. Its ISIN is INE877V01027.
Incorporated in 2005, Suraksha Diagnostic offers an integrated pathology, radiology testing, and medical consultancy services solution. [1]
Suraksha Diagnostic Limited operates an organized network of diagnostic centres across Eastern India offering integrated pathology, advanced radiology, genomics, and omnichannel medical consultations; the company runs multi-modality labs, 120 polyclinic chambers, and a broad test menu spanning routine pathology to advanced molecular and imaging services from a regional hub-and-spoke model.
Q3 FY'26 showed strong top-line momentum with revenue of INR783.09 million (up 30.3% YoY) driven by center additions and product mix shifts toward genomics; tests performed rose 30.7% YoY to 2.06 million while patients increased 23% YoY, indicating both volume-led growth and early traction for higher-value molecular services.
Listed peers in Healthcare Service Provider: Krsnaa Diagnostics Ltd, One Global Service Provider Ltd, Health X Platform Ltd, 3B Blackbio DX Ltd, Gaudium IVF and Women Health Ltd, Chandan Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹264.2 a share on 10 Jul 2026, Suraksha Diagnostic Ltd (SURAKSHA) was valued at a price-to-earnings ratio of 43.81x against an industry P/E of 61.73x and a price-to-book of 6.51x on a book value of ₹40.56 per share as of Mar 2025. Solomo computes return on equity of 14.87% and return on capital employed of 19.03% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 43.81x
- Industry P/E
- 61.73x
- P/B
- 6.51x
- EPS (TTM)
- ₹6.03
- Book value / share
- ₹40.56
- ROE
- 14.87%
- ROCE
- 19.03%
- ROA
- 9.42%
- Debt / equity
- 0.42x
- Dividend yield
- 0.19%
- EBITDA margin
- 31.75%
- 52-week range
- ₹224.1 – ₹333.65
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Suraksha Diagnostic Ltd (SURAKSHA) reported revenue of ₹310 crore, net profit of ₹31 crore and earnings per share of ₹6.18. That compares with revenue of ₹252 crore and net profit of ₹31 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹81.41 crore and net profit ₹6.16 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 223 | 190 | 219 | 252 | 310 |
| Net profit (₹ cr) | 24 | 6 | 23 | 31 | 31 |
| EPS (₹) | 344.2 | 94.49 | 342.46 | 6.11 | 6.18 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 9.60% | 3.73% | 15.26% |
| Profit growth | 17.06% | 12.08% | 33.94% |
| Stock price CAGR | - | - | -20% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 49.1% of Suraksha Diagnostic Ltd (SURAKSHA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 13.47% and domestic institutional investors (DII) hold 23.23%. Promoters have pledged 0.1% of their holding. Market capitalisation was ₹1,376 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2024.
Largest disclosed public shareholders in Jun 2026: ORBIMED ASIA II MAURITIUS LIMITED 12.88%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHA 7.48%, KOTAK SMALL CAP FUND 6.51%, ADITYA BIRLA SUN LIFE TRUSTEE PRIVATE LIMITED A/C 3.79%, CARNELIAN BHARAT AMRITKAAL FUND 2.37%, BANDHAN BALANCED ADVANTAGE FUND 1.32%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 49.1% | 0.1% | 13.47% | 23.23% | 50.9% |
| Mar 2026 | 49.1% | 0.1% | 13.46% | 23.14% | 50.9% |
| Dec 2025 | 49% | - | 13.46% | 22.57% | 51% |
| Sep 2025 | 48.98% | - | 13.72% | 21.98% | 51.02% |
| Jun 2025 | 48.88% | - | 13.95% | 22.37% | 51.12% |
| Mar 2025 | 48.78% | - | 14.46% | 22.05% | 51.22% |
| Dec 2024 | 48.78% | - | 15.39% | 20.44% | 51.22% |